Macquarie Group’s Akero Therapeutics AKRO Stock Holding History

Macquarie Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$1.19M	–	868
2025 Q3	$1.19M	Sell	25,000 -14,478	-37%	-$701K	﹤0.01%	1292
2025 Q2	$2.11M	Buy	39,478 +9,478	+32%	+$431K	﹤0.01%	1212
2025 Q1	$1.21M	Buy	+30,000	New	+$1.27M	﹤0.01%	1355
2023 Q4	–	Sell	-22,785	Closed	-$1.15M	–	1640
2023 Q3	$1.15M	Buy	+22,785	New	+$1.06M	﹤0.01%	1311
2022 Q4	–	Sell	-3,089	Closed	-$119K	–	1752
2022 Q3	$119K	Sell	3,089 -403	-12%	-$6.17K	﹤0.01%	1720
2022 Q2	$33K	Hold	3,492	–	–	﹤0.01%	2158
2022 Q1	$50K	Hold	3,492	–	–	﹤0.01%	2137
2021 Q4	$74K	Sell	3,492 -865	-20%	-$19.2K	﹤0.01%	2033
2021 Q3	$97K	Buy	+4,357	New	+$98.6K	﹤0.01%	1992

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group's AKRO Position: Q4 2025 in Review

Macquarie Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 25,000 shares — an estimated $1.19M sold.

Macquarie Group first reported a position in AKRO in Q3 2021 and held it in 9 quarters. The position peaked at $2.11M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Macquarie Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 25,000 Akero Therapeutics shares in Q4 2025, an estimated $1.19M.
Macquarie Group first reported a position in Akero Therapeutics in Q3 2021 and held it in 9 quarters.
Macquarie Group's Akero Therapeutics position peaked at $2.11M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.